The Lancet Healthy Longevity
Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials
Randomized trial in 1,024 peoplemTOR inhibitors
Clinically symptomatic respiratory illness
1 paper